中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 12
Dec.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(12): 2830-2835

Clinical significance and methods of hepatitis D virus RNA detection

DOI: 10.3969/j.issn.1001-5256.2022.12.028

  • Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China

Research funding:

National Natural Science Foundation of China (81871640);

National Natural Science Foundation of China (82172255)

More Information
  • Corresponding author: ZHANG Jiming, jmzhang@fudan.edu.cn (ORCID: 0000-0001-5820-950X)
  • Received Date: 2022-04-25
  • Accepted Date: 2022-05-26
  • Published Date: 2022-12-20
    Abstract
  • The prevalence and severity of hepatitis D virus (HDV) infection have always been underestimated, and the low screening and diagnosis rates may bring severe disease burden. HDV RNA, as the direct evidence of viral replication, is of great importance for the diagnosis and management of hepatitis D. This article summarizes the clinical significance of HDV RNA detection and introduces the advances in detection methods, in order to facilitate the screening and diagnosing of hepatitis D.

     

    • FullText(HTML)
  • loading
    • References(59)
  • [1]
    RIZZETTO M, CANESE MG, ARICÒ S, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers[J]. Gut, 1977, 18(12): 997-1003. DOI: 10.1136/gut.18.12.997.
    [2]
    RIZZETTO M, CANESE MG, GERIN JL, et al. Transmission of the hepatitis B virus-associated delta antigen to chimpanzees[J]. J Infect Dis, 1980, 141(5): 590-602. DOI: 10.1093/infdis/141.5.590.
    [3]
    LAI MM. The molecular biology of hepatitis delta virus[J]. Annu Rev Biochem, 1995, 64: 259-286. DOI: 10.1146/annurev.bi.64.070195.001355.
    [4]
    RADJEF N, GORDIEN E, IVANIUSHINA V, et al. Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades[J]. J Virol, 2004, 78(5): 2537-2544. DOI: 10.1128/jvi.78.5.2537-2544.2004.
    [5]
    DI BISCEGLIE AM, NEGRO F. Diagnosis of hepatitis delta virus infection[J]. Hepatology, 1989, 10(6): 1014-1016. DOI: 10.1002/hep.1840100621.
    [6]
    YURDAYDIN C, IDILMAN R, BOZKAYA H, et al. Natural history and treatment of chronic delta hepatitis[J]. J Viral Hepat, 2010, 17(11): 749-756. DOI: 10.1111/j.1365-2893.2010.01353.x.
    [7]
    ROMEO R, DEL NINNO E, RUMI M, et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma[J]. Gastroenterology, 2009, 136(5): 1629-1638. DOI: 10.1053/j.gastro.2009.01.052.
    [8]
    FATTOVICH G, GIUSTINA G, CHRISTENSEN E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep)[J]. Gut, 2000, 46(3): 420-426. DOI: 10.1136/gut.46.3.420.
    [9]
    PALOM A, RODRÍGUEZ-TAJES S, NAVASCUÉS CA, et al. Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia[J]. Aliment Pharmacol Ther, 2020, 51(1): 158-166. DOI: 10.1111/apt.15521.
    [10]
    MIAO Z, ZHANG S, OU X, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection[J]. J Infect Dis, 2020, 221(10): 1677-1687. DOI: 10.1093/infdis/jiz633.
    [11]
    STOCKDALE AJ, KREUELS B, HENRION M, et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis[J]. J Hepatol, 2020, 73(3): 523-532. DOI: 10.1016/j.jhep.2020.04.008.
    [12]
    CHEN HY, SHEN DT, JI DZ, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis[J]. Gut, 2019, 68(3): 512-521. DOI: 10.1136/gutjnl-2018-316601.
    [13]
    WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection[M]. Geneva, World Health Organization, 2015.
    [14]
    SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98. DOI: 10.1007/s12072-015-9675-4.
    [15]
    European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
    [16]
    TERRAULT NA, LOK A SF, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599.
    [17]
    MENTHA N, CLÉMENT S, NEGRO F, et al. A review on hepatitis D: From virology to new therapies[J]. J Adv Res, 2019, 17: 3-15. DOI: 10.1016/j.jare.2019.03.009.
    [18]
    COLLER KE, BUTLER EK, LUK KC, et al. Development and performance of prototype serologic and molecular tests for hepatitis delta infection[J]. Sci Rep, 2018, 8(1): 2095. DOI: 10.1038/s41598-018-20455-5.
    [19]
    WU S, ZHANG Y, TANG Y, et al. Molecular epidemiology and clinical characteristics of hepatitis delta virus (HDV) infected patients with elevated transaminases in Shanghai, China[J]. BMC Infect Dis, 2020, 20(1): 565. DOI: 10.1186/s12879-020-05275-1.
    [20]
    RIZZETTO M. Hepatitis D[M]//JOHNSON LR. Encyclopedia of Gastroenterology. New York, Elsevier, 2004: 334-337.
    [21]
    KAMAL H, WESTMAN G, FALCONER K, et al. Long-term study of hepatitis delta virus infection at secondary care centers: the impact of viremia on liver-related outcomes[J]. Hepatology, 2020, 72(4): 1177-1190. DOI: 10.1002/hep.31214.
    [22]
    ROMEO R, FOGLIENI B, CASAZZA G, et al. High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta[J]. PLoS One, 2014, 9(3): e92062. DOI: 10.1371/journal.pone.0092062.
    [23]
    WRANKE A, SERRANO BC, HEIDRICH B, et al. Antiviral treatment and liver-related complications in hepatitis delta[J]. Hepatology, 2017, 65(2): 414-425. DOI: 10.1002/hep.28876.
    [24]
    WEDEMEYER H, YURDAYDIN C, HARDTKE S, et al. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-Ⅱ): a randomised, placebo controlled, phase 2 trial[J]. Lancet Infect Dis, 2019, 19(3): 275-286. DOI: 10.1016/S1473-3099(18)30663-7.
    [25]
    BREMER B, ANASTASIOU OE, HARDTKE S, et al. Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-Ⅱ study[J]. Liver Int, 2021, 41(2): 295-299. DOI: 10.1111/liv.14740.
    [26]
    FARCI P, ROSKAMS T, CHESSA L, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis[J]. Gastroenterology, 2004, 126(7): 1740-1749. DOI: 10.1053/j.gastro.2004.03.017.
    [27]
    KESKIN O, WEDEMEYER H, TVZVN A, et al. Association between level of hepatitis D virus RNA at week 24 of pegylated interferon therapy and outcome[J]. Clin Gastroenterol Hepatol, 2015, 13(13): 2342-2349. e1-2. DOI: 10.1016/j.cgh.2015.05.029.
    [28]
    ERHARDT A, GERLICH W, STARKE C, et al. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b[J]. Liver Int, 2006, 26(7): 805-810. DOI: 10.1111/j.1478-3231.2006.01279.x.
    [29]
    KARACA C, SOYER OM, BARAN B, et al. Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response[J]. Antivir Ther, 2013, 18(4): 561-566. DOI: 10.3851/IMP2381.
    [30]
    YURDAYDIN C, KESKIN O, KALKAN Ç, et al. Interferon treatment duration in patients with chronic delta hepatitis and its effect on the natural course of the disease[J]. J Infect Dis, 2018, 217(8): 1184-1192. DOI: 10.1093/infdis/jix656.
    [31]
    KOH C, DA BL, GLENN JS. HBV/HDV coinfection: A challenge for therapeutics[J]. Clin Liver Dis, 2019, 23(3): 557-572. DOI: 10.1016/j.cld.2019.04.005.
    [32]
    YURDAYDIN C, ABBAS Z, BUTI M, et al. Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy[J]. J Hepatol, 2019, 70(5): 1008-1015. DOI: 10.1016/j.jhep.2018.12.022.
    [33]
    LE GAL F, GAULT E, RIPAULT MP, et al. Eighth major clade for hepatitis delta virus[J]. Emerg Infect Dis, 2006, 12(9): 1447-1450. DOI: 10.3201/eid1209.060112.
    [34]
    LE GAL F, BRICHLER S, DRUGAN T, et al. Genetic diversity and worldwide distribution of the deltavirus genus: A study of 2, 152 clinical strains[J]. Hepatology, 2017, 66(6): 1826-1841. DOI: 10.1002/hep.29574.
    [35]
    SU CW, HUANG YH, HUO TI, et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients[J]. Gastroenterology, 2006, 130(6): 1625-1635. DOI: 10.1053/j.gastro.2006.01.035.
    [36]
    GOMES-GOUVÊA MS, SOARES M, BENSABATH G, et al. Hepatitis B virus and hepatitis delta virus genotypes in outbreaks of fulminant hepatitis (Labrea black fever) in the western Brazilian Amazon region[J]. J Gen Virol, 2009, 90(Pt 11): 2638-2643. DOI: 10.1099/vir.0.013615-0.
    [37]
    ROULOT D, BRICHLER S, LAYESE R, et al. Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta[J]. J Hepatol, 2020, 73(5): 1046-1062. DOI: 10.1016/j.jhep.2020.06.038.
    [38]
    WANG W, LEMPP FA, SCHLUND F, et al. Assembly and infection efficacy of hepatitis B virus surface protein exchanges in 8 hepatitis D virus genotype isolates[J]. J Hepatol, 2021, 75(2): 311-323. DOI: 10.1016/j.jhep.2021.03.025.
    [39]
    HSU SC, SYU WJ, SHEEN IJ, et al. Varied assembly and RNA editing efficiencies between genotypes Ⅰ and Ⅱ hepatitis D virus and their implications[J]. Hepatology, 2002, 35(3): 665-672. DOI: 10.1053/jhep.2002.31777.
    [40]
    SALDANHA J, DI BLASI F, BLAS C, et al. Detection of hepatitis delta virus RNA in chronic liver disease[J]. J Hepatol, 1989, 9(1): 23-28. DOI: 10.1016/0168-8278(89)90071-8.
    [41]
    MADEJÓN A, CASTILLO I, BARTOLOMÉ J, et al. Detection of HDV-RNA by PCR in serum of patients with chronic HDV infection[J]. J Hepatol, 1990, 11(3): 381-384. DOI: 10.1016/0168-8278(90)90225-g.
    [42]
    CHEN PJ, KALPANA G, GOLDBERG J, et al. Structure and replication of the genome of the hepatitis delta virus[J]. Proc Natl Acad Sci U S A, 1986, 83(22): 8774-8778. DOI: 10.1073/pnas.83.22.8774.
    [43]
    SAIKI RK, SCHARF S, FALOONA F, et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia[J]. Science, 1985, 230(4732): 1350-1354. DOI: 10.1126/science.2999980.
    [44]
    HAFF LA. Improved quantitative PCR using nested primers[J]. PCR Methods Appl, 1994, 3(6): 332-337. DOI: 10.1101/gr.3.6.332.
    [45]
    WITTWER CT, HERRMANN MG, MOSS AA, et al. Continuous fluorescence monitoring of rapid cycle DNA amplification[J]. Biotechniques, 1997, 22(1): 130-131, 134-138. DOI: 10.2144/97221bi01.
    [46]
    NAVARRO E, SERRANO-HERAS G, CASTAÑO MJ, et al. Real-time PCR detection chemistry[J]. Clin Chim Acta, 2015, 439: 231-250. DOI: 10.1016/j.cca.2014.10.017.
    [47]
    YAMASHIRO T, NAGAYAMA K, ENOMOTO N, et al. Quantitation of the level of hepatitis delta virus RNA in serum, by real-time polymerase chain reaction--and its possible correlation with the clinical stage of liver disease[J]. J Infect Dis, 2004, 189(7): 1151-1157. DOI: 10.1086/382133.
    [48]
    LE GAL F, GORDIEN E, AFFOLABI D, et al. Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients[J]. J Clin Microbiol, 2005, 43(5): 2363-2369. DOI: 10.1128/JCM.43.5.2363-2369.2005.
    [49]
    LE GAL F, BRICHLER S, SAHLI R, et al. First international external quality assessment for hepatitis delta virus RNA quantification in plasma[J]. Hepatology, 2016, 64(5): 1483-1494. DOI: 10.1002/hep.28772.
    [50]
    WANG Y, GLENN JS, WINTERS MA, et al. A new dual-targeting real-time RT-PCR assay for hepatitis D virus RNA detection[J]. Diagn Microbiol Infect Dis, 2018, 92(2): 112-117. DOI: 10.1016/j.diagmicrobio.2018.05.016.
    [51]
    HOMS M, GIERSCH K, BLASI M, et al. Relevance of a full-length genomic RNA standard and a thermal-shock step for optimal hepatitis delta virus quantification[J]. J Clin Microbiol, 2014, 52(9): 3334-3338. DOI: 10.1128/JCM.00940-14.
    [52]
    OLIVERO A, ABATE M L, NIRO G, et al. A novel approach for hepatitis delta virus viremia quantification by droplet digital PCR assay[J]. J Hepatol, 2016, 64(2): S354. DOI: 10.1016/s0168-8278(16)00518-3.
    [53]
    NOTOMI T, OKAYAMA H, MASUBUCHI H, et al. Loop-mediated isothermal amplification of DNA[J]. Nucleic Acids Res, 2000, 28(12): E63. DOI: 10.1093/nar/28.12.e63.
    [54]
    WANG C, SHEN X, LU J, et al. Development of a reverse transcription-loop-mediated isothermal amplification (RT-LAMP) system for rapid detection of HDV genotype 1[J]. Lett Appl Microbiol, 2013, 56(3): 229-235. DOI: 10.1111/lam.12039.
    [55]
    SOROKA M, WASOWICZ B, RYMASZEWSKA A. Loop-Mediated Isothermal Amplification (LAMP): The better sibling of PCR?[J]. Cells, 2021, 10(8). DOI: 10.3390/cells10081931.
    [56]
    SCHAPER M, RODRIGUEZ-FRIAS F, JARDI R, et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D[J]. J Hepatol, 2010, 52(5): 658-664. DOI: 10.1016/j.jhep.2009.10.036.
    [57]
    KARATAYLI E, ALTUNOĜLU YÇ, KARATAYLI SC, et al. A one step real time PCR method for the quantification of hepatitis delta virus RNA using an external armored RNA standard and intrinsic internal control[J]. J Clin Virol, 2014, 60(1): 11-15. DOI: 10.1016/j.jcv.2014.01.021.
    [58]
    CHUDY M, HANSCHMANN KM, BOZDAYI M, et al. Collaborative study to establish a World Health Organization international standard for hepatitis D virus RNA for nucleic acid amplification technique (NAT)-based assays[R]. Geneva: World Health Organization, 2013.
    [59]
    SCHELLER L, HILGARD G, ANASTASIOU O, et al. Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients[J]. Medicine (Baltimore), 2021, 100(28): e26571. DOI: 10.1097/MD.0000000000026571.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1555) PDF downloads(124) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return